NIAID Banner Logo Image

TB Drugs in Development


Drug ClassSponsor and/or CompanyDrug NameAlt NameDrug StatusNotesAIDS#
ATP Synthase InhibitorGlobal Alliance for TB Drug DevelopmentTBAJ-876 Phase 1Active, Not Recruiting 
Antibody, MonoclonalNational University, SingaporePascolizumabAnti-IL-4 AntibodyPhase 2Unknown 
Cell Wall Synthesis InhibitorGlobal Alliance for TB Drug DevelopmentTBA-7371An azaindolePhase 2Recruiting 555726
Cell Wall Synthesis InhibitorEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Michael Hoelscher, Ludwig-Maximilians, University of MunichBTZ043Benzothiazinone derivativePhase 1/2Recruiting 538411
Cell Wall Synthesis InhibitorUniversity Medical Center GroningenInvanz™ErtapenemPhase 2Completed 604819
Cell Wall Synthesis InhibitorNational University, Singapore; Asubio PharmaFarom™FaropenemPhase 2Completed 545326
Cell Wall Synthesis InhibitorEuropean and Developing Countries Clinical Trials Partnership (EDCTP); SequellaSQ-109A novel 1,2-ethylene diaminePhase 2Completed 207396
Cell Wall Synthesis InhibitorInnovative Medicines for Tuberculosis; Nearmedic Plus LLCMacozinoneMCZ; PBTZ-169Phase 1Completed 573761
Cell Wall Synthesis InhibitorOtsuka PharmOPC-167832 3,4-dihydrocarbostyril derivativePhase 1/2Recruiting 
Cell Wall Synthesis InhibitorJohns Hopkins UniversityMerrem™Meropenem; SM-7338Phase 2Recruiting 007788
Cholesterol Catabolism InhibitorGlaxoSmithKlineGSK2556286GSK-286Phase 1Recruiting 
CombinationThe HIV Netherlands Australia Thailand Research CollaborationIndinavir & Ritonavir & Rifampicin Phase 1/2Completed 
CombinationUniversity Medical Center Groningen, NetherlandsIsoniazid & Co-Trimoxazole (Trimethoprim & Sulfamethoxazole) Phase 3Completed 
CombinationNational University Hospital, SingaporeFaropenem & Amoxicillin (Clavulanic Acid) & Cefadroxil & Rifampicin Phase 2Completed 
CombinationNational Institute of Allergy and Infectious Diseases (NIAID)Imatinib & Isoniazid & Rifabutin Phase 2Recruiting 
CombinationWalter K. Kraft, Thomas Jefferson University; Merck Sharp & Dohme Corp.Doravirine & Rifapentine & IsoniazidCombination for Latent Tuberculosis TreatmentPhase 1Completed 
CombinationPfizerLersivirine (UK-453,061) & Rifabutin Phase 1Completed 
CombinationNational University Hospital, SingaporeCelecoxib & Rifampicin & Pyrazinamide Phase 1Completed 
CombinationNational Taiwan University HospitalRifapentine & IsoniazidCombination for Latent Tuberculosis TreatmentPhase 3Recruiting 070133
CombinationGlobal Alliance for TB Drug DevelopmentMidazolam & PA-824 Phase 1Completed 
CombinationGlobal Alliance for TB Drug DevelopmentBPaMZBedaquiline & Pretomanid & Moxifloxacin & PyrazinamidePhase 2/3Active, Not Recruiting 
Cytochrome bc1 Complex InhibitorQurient Co., Ltd.Telacebec Q203Phase 2Completed 594207
DNA Methyltransferase InhibitorBaylor College of Medicine; Celgene CorporationVidaza™Azacitidine; AzacytidinePhase 1/2Not Yet Recruiting 000615
DNA Replication Inhibitor/TB Cell Division InhibitorNational Institute of Allergy and Infectious Diseases (NIAID); Parke-Davis; Kyorin Pharm; PfizerTequin™Gatifloxacin; GTFX; BMS-206584; AM-1155; CG 5501; PD-135432; GATPhase 3Unknown 044913
DNA Replication Inhibitor/TB Cell Division InhibitorIUATLD, Inc ; Daiichi Pharm; Sanofi-Aventis; Ortho-McneilLevaquin™; Tavanic™S-(-)-Ofloxacin; DR-3355; RWJ-25213; Cravit; L-Ofloxacin; Levofloxacin; LVXPhase 3Active, Not Recruiting 002307
DNA Replication Inhibitor/TB Cell Division InhibitorGlobal Alliance for TB Drug Development; Bayer; Schering-PloughAvelox™Moxifloxacin; MXFX; BAY 12-8039; Actira; AveloxPhase 3Completed 070017
DNA Replication Inhibitor/TB Cell Division InhibitorNational Institute of Allergy and Infectious Diseases (NIAID); BayerFlagyl™Metronidazole; Bayer 5360; Clont; Danizol; Gineflavir; Metric 21; Trichazol; Trichopal; Trivazol; VagilenPhase 2Completed 007953
GyrB ATPase InhibitorSpero Therapeutics, LLCSPR720VXc-100, VXc-486; An ethyl urea benzimidazolePhase 1Completed 
Host-directed TherapyJohns Hopkins UniversityPravachol™PravastatinPhase 2Recruiting 488445
Leucyl-tRNA Synthetase (LeuRS) InhibitorGlaxoSmithKlineGSK3036656GSK070Phase 2Recruiting 599488
Mycolic Acid Biosynthesis InhibitorWits Health Consortium (Pty) Ltd; Otsuka PharmDeltyba™Delamanid; OPC-67683Phase 3Recruiting 182259
Protein Synthesis InhibitorMicuRx PharmaceuticalsMRX-4Prodrug of Contezolid (MRX-1)Phase 1Completed 
Protein Synthesis Inhibitor/TB Growth InhibitorLegoChem Biosciences, Inc.DelpazolidLCB01-0371Phase 2Completed 581214
Protein Synthesis Inhibitor/TB Growth InhibitorEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Pharmacia & Upjohn, Inc.; PfizerSutezolidPNU-100480; PF-02341272; OxazolidininonePhase 2Not Yet Recruiting 045415
Protein Synthesis Inhibitor/TB Growth InhibitorGlobal Alliance for TB Drug DevelopmentTBI-223Novel oxazolidinonePhase 1Active, Not Recruiting 592820
Protein Synthesis Inhibitor/TB Growth InhibitorNational University Hospital, SingaporeVibramycin™DoxycyclinePhase 2Completed 000242
Protein Synthesis Inhibitor/TB Growth InhibitorGlobal Alliance for TB Drug Development; Pharmacia & Upjohn, Inc.; PfizerZyvox™Linezolid; LZD; PNU-100766Phase 3Active, Not Recruiting 070944
Pyruvate-Ferredoxin Oxidoreductase InhibitorWeill Medical College of Cornell UniversityAlinia™ ; Nizonide™NitazoxanidePhase 2Completed 057131
UnidentifiedScientific Center for Anti-infectious Drugs, KazakhstanFS-1Molecular iodine complex with bioorganic ligands, magnesium and lithium halogenidesPhase 3Active, Not Recruiting 

Sources: ClinicalTrials.gov and sponsor websites.

If using ChemDB information for publication or abstract presentation, please cite the website in addition to the original information source.    Database last updated: May 2021